SYK inhibition and response prediction in diffuse large B-cell lymphoma. - Wikidata - awgldk - TriplyDB

SYK inhibition and response prediction in diffuse large B-cell lymphoma.

SYK inhibition and response prediction in diffuse large B-cell lymphoma.

http://www.wikidata.org/entity/Q39453213

about

Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinib Targeting the B-cell receptor signaling pathway in B lymphoid malignancies Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review Crystal structures of spleen tyrosine kinase in complex with novel inhibitors: structural insights for design of anticancer drugs Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules.Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma.Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer Syk interacts with and phosphorylates nucleolin to stabilize Bcl-x(L) mRNA and promote cell survival.A signaling network stimulated by β2 integrin promotes the polarization of lytic granules in cytotoxic cells Calling in SYK: SYK's dual role as a tumor promoter and tumor suppressor in cancer.Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia.Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells.Novel Agents and Emerging Strategies for Targeting the B-Cell Receptor Pathway in CLL Suppression of CD300A inhibits the growth of diffuse large B-cell lymphoma.The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib Quantitative immunofluorescence reveals the signature of active B-cell receptor signaling in diffuse large B-cell lymphoma.Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs.Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment.Identification of distinct molecular subtypes of uterine carcinosarcoma Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders.Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling B-cell receptor signaling inhibitors for treatment of autoimmune inflammatory diseases and B-cell malignancies.Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas.Pharmacodynamic considerations of small molecule targeted therapy for treating B-cell malignancies in the elderly.Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment Targeting childhood, adolescent and young adult non-Hodgkin lymphoma: therapeutic horizons.Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition.Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma.Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma.Role of the immunoreceptor tyrosine-based activation motif of latent membrane protein 2A (LMP2A) in Epstein-Barr virus LMP2A-induced cell transformation.Expression and pro-survival function of phospholipase Cγ2 in diffuse large B-cell lymphoma.SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers Global gene expression changes of in vitro stimulated human transformed germinal centre B cells as surrogate for oncogenic pathway activation in individual aggressive B cell lymphomas Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line che Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells.HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment.

P2860

Q26744277-C189BB2C-30F0-4298-8393-5DE985081E00 Q26828782-126D591A-33C7-4C4F-8449-330773B3C1F4 Q27304386-66A08CCC-D8C1-41AF-BD6C-AEC74D4073F5 Q27726998-20601D08-8A75-452B-A317-9A5C3D71E25A Q27853177-55ED4C4A-0E4B-4415-9A04-44EA77F580F7 Q33409872-F89CB370-1225-4714-9CF2-E739AF628067 Q33622342-1AEE62F6-0280-49CF-A6AE-710F360D019F Q33643375-EB3BBA1D-C23A-4FAB-B329-0A514CCC2546 Q34297938-B5D042BE-68F9-4378-A4F4-290CA05AF997 Q34383550-AFAEBD61-1000-4F42-B9EE-B43E896C8F28 Q34625171-4A056673-0043-44CE-A36A-6D3C6C2372F6 Q36201677-857A28CB-D9F2-46EB-8D4E-E9A2B4D1D080 Q36217436-6B90B307-BB8E-499B-8076-18845A417F85 Q36404778-01A1F5C7-6FD4-4BB6-A6A3-457E14BDEBD6 Q36544524-369FCBEC-D082-484B-A68B-008E64ADE8F4 Q36573201-8A6B5C73-7F0B-4F67-A88F-E2C4EA155FF2 Q36782516-08C73B3B-CB7F-4FD8-AD16-9820506F016A Q37494320-49F13F4E-6A41-491A-90D2-E3038B0D957F Q37618835-1996820F-1A64-4A8B-9F8E-276E666B797C Q37706530-E8CB5B9E-550F-47BF-867A-7B8345D0C774 Q37716634-D9AE94DB-AC59-4DBB-B529-DE1007EC9A2E Q38011765-768991C4-0037-4DD1-AF59-D3EBC504BCD0 Q38069567-A9048A11-5D9F-4C39-9E66-B61E88EF6E52 Q38124120-6B280992-CF93-4920-A72A-127F3C2DFC82 Q38433704-0BE64BFB-5280-4A6B-BF1C-5C6062D2327A Q38544216-DD7A5D8B-545A-45BD-A41A-86156F75BB5E Q38714409-1FBDA8FB-2C32-4D82-9369-5DBDE130827C Q38790957-69477C93-C440-4389-B2D1-2ACE49B68B1B Q38796456-E05A634D-F910-4ACB-949D-51C246E43152 Q38819065-04A55437-70CB-46E0-BAE5-0AB838022C0A Q38849166-7F5E3547-204F-4F55-9F3F-1C186B275C22 Q38860330-0B51748A-7267-4C85-B227-25AB8B7E8AA7 Q38976449-8A0D1DA5-3D11-49C5-9905-8108FB0F6343 Q39140068-B6FE51B6-806E-4F4A-B7E5-5B06FBE87B68 Q39608430-1394323F-78A4-46EB-87D5-EFDDEE771F51 Q42005623-7A0D40F2-9044-4130-B891-37B3A44624EA Q42221150-B98B83DA-9108-4804-BF52-A1C28478EB0A Q50247640-963C80D7-1CC2-4931-A6C4-25771E15E597 Q51072600-3571873D-D168-487B-B59F-D0FB7EC95640 Q51173647-770D7873-84CC-4ABD-8155-3FBD3DC5CC8D

P2860

SYK inhibition and response prediction in diffuse large B-cell lymphoma.

http://www.wikidata.org/entity/Q39453213

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

SYK inhibition and response prediction in diffuse large B-cell lymphoma.

@en

SYK inhibition and response prediction in diffuse large B-cell lymphoma.

@nl

type

label

SYK inhibition and response prediction in diffuse large B-cell lymphoma.

@en

SYK inhibition and response prediction in diffuse large B-cell lymphoma.

@nl

prefLabel

SYK inhibition and response prediction in diffuse large B-cell lymphoma.

@en

SYK inhibition and response prediction in diffuse large B-cell lymphoma.

@nl

P1433

Q39453213-DEF6D7A9-5683-400A-82CD-71C103B21EA2

P1476

Q39453213-01DE0527-6282-4F10-8ADB-B71FDFA37B01

P2093

Q39453213-0498A6F8-FC13-48AC-B7B9-426D2065870B

Q39453213-175662BF-F95F-4392-9672-701D1AE2FAFA

Q39453213-418DF526-4452-469E-B18A-6C99B4ED9209

Q39453213-54577D99-EF7E-4F0C-A1A0-232C70E0B5A2

Q39453213-611A29D7-8BF7-4AA4-B18A-033510A2939E

Q39453213-6EC42466-0FFE-4EAC-9FA5-D53EAB6BEF91

Q39453213-7DB92D7D-E982-4A67-B9C4-7B6114532EF6

Q39453213-81520566-7765-4693-B70F-4F5646A538F6

Q39453213-A90D7C41-6124-4C6C-A54B-7A6D0086A28B

Q39453213-BAC1920B-B3CD-4FAD-B25E-1D3C14E0CEFD

P304

Q39453213-C3B8D9DA-1CCF-4EAB-ACA7-04BFF0F78150

P31

Q39453213-B3F8442D-2D47-4AD3-976C-5E889362182C

P356

Q39453213-6A576F3C-770C-4868-ADC2-444C421A2901

P407

Q39453213-923901E1-8498-490F-847E-6C2CDC7A472F

P433

Q39453213-4DEC7BFE-29AD-476B-8260-B71B7B0145E2

P478

Q39453213-B7B27783-EE3B-4618-97F8-C32FE6636900

P577

Q39453213-875D12D6-309A-4584-A504-5B01CCEEC210

P5875

Q39453213-AC0ABAAC-35E9-40FB-AA02-4ECFFDA0939C

P698

Q39453213-079A9E21-CEDA-4C4F-9C77-3C8CC5DEC17A

P356

BLOOD-2011-02-333773

P1433

P1476

SYK inhibition and response prediction in diffuse large B-cell lymphoma.

@en

P2093

Anjali Pandey

http://www.w3.org/2001/XMLSchema#string

Ari M Melnick

http://www.w3.org/2001/XMLSchema#string

Greg Coffey

http://www.w3.org/2001/XMLSchema#string

Pin Lu

http://www.w3.org/2001/XMLSchema#string

Rita Shaknovich

http://www.w3.org/2001/XMLSchema#string

Shuhua Cheng

http://www.w3.org/2001/XMLSchema#string

Uma Sinha

http://www.w3.org/2001/XMLSchema#string

X Hannah Zhang

http://www.w3.org/2001/XMLSchema#string

Y Lynn Wang

http://www.w3.org/2001/XMLSchema#string

Zibo Song

http://www.w3.org/2001/XMLSchema#string

P304

6342-6352

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2011-02-333773

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P577

2011-10-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51743616

http://www.w3.org/2001/XMLSchema#string

P698

22025527

http://www.w3.org/2001/XMLSchema#string